The HOPE Study – Approaching Dementia Treatment Differently Lori La Bey talks with Ralph Kern, M.D., who is Chief Medical Officer at Cognito Therapeutics, a company developing a disease-modifying at-home therapy for Alzheimer’s Disease. He has over 17 years of biotech experience including senior medical roles at Genzyme, Novartis, and Biogen. Learn: About brain changes Lifestyle factors and genetics If early diagnosis helps At home treatment Light, sound, sensory stimulation Biophysical changes Decreased clinic visits HOPE Study    Watch the Video Interview Below https://youtu.be/dRY6PWEvZds   Listen and Subscribe to Alzheimer’s Speaks on Apple Podcast https://podcasts.apple.com/us/podcast/alzheimers-speaks/id986940432   Listen and Subscribe to Alzheimer’s Speaks on Spotify https://open.spotify.com/show/255okRnEgfCUqXq1NWcrT3   Contact Cognito Therapeutics Inc.  LinkedIn for Cognito Therapeutics - https://www.linkedin.com/company/cognito-therapeutics-inc./ Twitter for Cognito Therapeutics - @cognitotx LinkedIn for Ralph Kern - https://www.linkedin.com/in/ralphkernsvpbiotech/ Cognito website - www.cognitotx.com HOPE study website - www.hopestudyforad.com   Contact Lori La Bey with questions or branding needs at https://www.alzheimersspeaks.com/ Alzheimer's Speaks Radio - Shifting dementia care from crisis to comfort around the world one episode at a time by raising all voices and delivering sound news, not just sound bites since 2011. Alzheimer's Speaks is part of the Senior Resource Podcast NetworkSupport this Show: https://alzheimersspeaks.com/donate-now/See omnystudio.com/listener for privacy information.

Ver todos los episodios